Reports of New and Recurrent Keratitis following mRNA-based COVID-19 Vaccination.
COVID-19
Cornea
inflammation
keratitis
vaccine
Journal
Ocular immunology and inflammation
ISSN: 1744-5078
Titre abrégé: Ocul Immunol Inflamm
Pays: England
ID NLM: 9312169
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
medline:
2
8
2023
pubmed:
9
11
2022
entrez:
8
11
2022
Statut:
ppublish
Résumé
As ophthalmic side effects of messenger RNA (mRNA)-based COVID-19 vaccination are not well understood, it is crucial to document and report such instances should they occur. In this observational case series, we report nine patients (55.6% male, mean age 58.9) who received either the BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccinations from January to June of 2021, and presented with symptoms of keratitis within 14 days. All patients underwent slit-lamp examination and histories were taken. Most subjects (66.7%) had a history of corneal inflammatory diseases and resolved under antiviral and/or steroidal treatment. Patients who reported symptoms after their second vaccine dose presented earlier than those who reported symptoms after the first dose (mean 4.4 days vs 10.5 days, respectively). The immunological reaction following mRNA-based COVID-19 vaccinations may trigger new-onset or reactivation of keratitis, though causality cannot be proven. Despite its rarity, clinicians should be aware of this possible complication and be prepared to treat.
Identifiants
pubmed: 36345233
doi: 10.1080/09273948.2022.2133730
doi:
Substances chimiques
BNT162 Vaccine
0
COVID-19 Vaccines
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM